Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
CymaBay: Positive Phase 3 Data And Competitive Advantage Established
06:05am, Sunday, 10'th Sep 2023
Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to addit
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
02:17pm, Friday, 08'th Sep 2023
CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up.
Why CymaBay Therapeutics Stock Is Jumping Today
11:59am, Friday, 08'th Sep 2023
CymaBay announced positive results on Thursday for its treatment for a rare liver disease. The company now plans to talk with regulators about filing for approvals.
CymaBay Therapeutics stock jumps as rare liver disease treatment shows positive results
08:04am, Thursday, 07'th Sep 2023
Shares of CymaBay Therapeutics Inc. CBAY gained 23% premarket on Thursday after the company released positive results from a late-stage study of seladelpar, its investigational treatment for the rare
CymaBay's Seladelpar: An Exceptional PPAR Agonist Candidate For PBC
06:50am, Thursday, 20'th Jul 2023
CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant a
Recent Price Trend in CymaBay Therapeutics Inc. (CBAY) is Your Friend, Here's Why
10:35am, Monday, 17'th Jul 2023
CymaBay Therapeutics Inc. (CBAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that pas
Why Shares of CymaBay Therapeutics Are Soaring Friday
11:50am, Friday, 30'th Jun 2023
CymaBay is a clinical-stage biotech. The company focuses on liver diseases and other chronic diseases.
Two abstracts focus on the unique mechanism of action of seladelpar; a third focuses on characterizing patient risk of PBC disease progression NEWARK, Calif. , June 7, 2023 /PRNewswire/ -- CymaBay Th
Why CymaBay Therapeutics Stock Nose-Dived This Week
05:59pm, Friday, 19'th May 2023
The clinical-stage liver and other chronic disease specialist published its first-quarter results, which included a business update. The company's net loss was deeper than analysts expected.
CymaBay Therapeutics Inc. (CBAY) Is a Great Choice for 'Trend' Investors, Here's Why
09:53am, Tuesday, 16'th May 2023
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CymaBay Therapeutics, Inc. (CBAY) Q1 2023 Earnings Call Transcript
10:52pm, Monday, 15'th May 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - President and Chief Executive Office
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
08:00am, Wednesday, 10'th May 2023
NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea
CymaBay Therapeutics: Slow But Steady Progress
02:45pm, Tuesday, 09'th May 2023
Today, we shine the spotlight on CymaBay Therapeutics, Inc., whose stock has had a big rally in 2023. The company is advancing its lead asset Seladelpar towards approval and recently signed a licensin
Four Potential Breakout Stocks For The Rest Of The Week - Asure Software (NASDAQ:ASUR), CymaBay Therapeutics (NASDAQ:CBAY)
08:58am, Wednesday, 19'th Apr 2023
In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E.
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
08:00am, Monday, 17'th Apr 2023
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dis
